Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

Inclusion Criteria:Adult aged 19 or older at the time of the baseline visit.A patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement.Patients who were previously taking more than two tablets of a single drug, low-density lipoprotein-cholesterol (LDL-C)Patients who were previously only taking blood pressure-lowering drugs and did not take LDL-C-lowering drugs, but who need to take additional LDL-C-lowering drugs at the discretion of the researcherPatients who were previously taking LDL-C lowering agents and did not take blood pressure lowering agents, but who need to take additional blood pressure lowering agents according to the researcher's judgmentPatients who have not previously taken both a blood pressure drop and an LDL-C drop but need additional simultaneous use at the discretion of the researcherA person who can understand the information provided to him/her and may voluntarily sign a written consent formExclusion Criteria:A person who falls under the prohibition of administration according to the permission for olomax tabletA person who has a history of administering olomax tablets before participating in this studyIn addition to the above, a person that the investigator thinks he/she is not suitable for participating in this observation study;